Aliphatic propargylamines: New antiapoptotic drugs

Drug Development Research

Volumn 42, Issue 3-4, 1997, Pages 150-156

  Boulton, Alan A ^a   Davis, Bruce A ^a   Durden, David A ^a   Dyck, Lillian E ^a   Juorio, Augusto V ^a   Li, Xin Min ^a   Paterson, I Alick ^a   Yu, Peter H ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Aliphatic propargylamines; Apoptosis; Monoamine oxidase B inhibitors; Neural rescue

Indexed keywords

MONOAMINE OXIDASE B INHIBITOR; NEUROPROTECTIVE AGENT; PROPARGYLAMINE DERIVATIVE; SELEGILINE; UNCLASSIFIED DRUG;

APOPTOSIS; DOPAMINE METABOLISM; DRUG BIOAVAILABILITY; DRUG SYNTHESIS; ENANTIOMER; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; NEUROPROTECTION; NONHUMAN; REVIEW; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 0031393126     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199711/12)42:3/4<150::AID-DDR6>3.0.CO;2-P     Document Type: Review

References (88)

1. Allain H, Cougnand J, Neukinch HC (1991): Selegiline in de novo Parkinsonian patients: The French selegiline multicenter trial (FSMT). Acta Neurol Scand 84(Suppl 136):73-78.
2. Ansari KS, Yu PH, Kruck TX, Tatton WG (1993): Death of axotomised immature rat facial motor neurones: Stereospecific rescue by R(-)deprenyl independently of MAO inhibition. J Neurosci 13:4042-4053.
3. Berry MD, Juorio AV, Paterson IA (1994a): The functional role of monoamine oxidase A and B in the mammalian central nervous system. Prog Neurobiol 42:375-391.
4. Berry MD, Juorio AV, Paterson IA (1994b): Possible mechanisms of action of (-) deprenyl and other MAO-B inhibitors in some neurological and psychiatric disorders. Prog Neurobiol 44:141-161.
5. Bertocci B, Gill G, DaPrada M (1988): Prevention of the DSP-4-induced noradrenergic neurotoxicity by irreversible, not by reversible, MAO-B inhibitors. Pharmacol Res Commun 20:131-132.
6. Biagini G, Zoli M, Fuxe K, Agnati LF (1993): L-Deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brain. NeuroReport 4:955-958.
7. Boulton AA, Eisenhofer G (1998): Catecholamine metabolism: From molecular understanding to clinical diagnosis and treatment. Adv Pharmacol 42:273-292.
8. Boulton AA, Yu PH, Davis BA, Paterson IA, Li X-M, Juorio AV, Durden DA, Dyck LE (1998): Aliphatic N-methylpropargylamines: Monoamine oxidase B inhibitors and antiapoptotic drugs. Adv Pharmacol 42:308-311.
9. Bruyette DS, Ruehl WW, Smidberg TL (1995): Canine pituitary-dependent hyperadrenocorticism: A spontaneous animal model for neurodegenerative disorders and their treatment with L-deprenyl. Prog Brain Res 106:207-215.
10. Buys YM, Trope GM, Tatton WG (1995): (-)Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr Eye Res 14:119-126.
11. Durden DD, Paterson IA, Davis BA, Yu PH, Li X-M, Boulton AA (1997): Aliphatic propargylamines as cellular rescue agents. Patent filed USA, July 14, 1997.
12. Ecseri Z, Müller M, Knoll J, Somfui E (1964): Hungarian Patent #151090.
13. Fang J, Yu PH (1994): Effects of L-deprenyl, its structural analogues and some MAO inhibitors on dopamine uptake. Neuropharmacology 33:763-768.
14. Fang J, Zuo DM, Yu PH (1995): Lack of protective effect of R(-)deprenyl on programmed cell death of mouse thymocytes induced by dexamethasone. Life Sci 57:15-22.
15. Filip V, Davis I, Klaschka J, Kolibas E (1997): Selegiline slows down the decline of cognitive and electrophysiological functions in Alzheimer's disease. In Judd LL, Saleta B, Filip V (eds): Basic and Clinical Science of Mental and Addictive Disorders. Basel: Karger, pp 238-240.
16. Finnegan KT, Skratt JS, Irwin I, Delanney LE, Langston J-W (1990): Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 184:119-126.
17. Freisleben HJ, Lehr F, Fuchs J (1994): Lifespan of immunosuppressed NMRI-mice is increased by deprenyl. J Neural Transm (Suppl): 41:231-236.
18. Freisleben HJ, Neeb A, Lehr F, Ackerman H (1997): Influence of selegiline and lipoic acid on the life expectancy of immunosuppressed mice. Arz Forsh/Drug Res 47:776-780.
19. Gelowitz DL (1997): Antiapoptotic actions of (-)deprenyl in the CNS: Pharmacological, histological and behavioural evidence. Ph.D. Thesis, University of Saskatchewan.
20. Grace JM, Kinter MT, Macdonald TL (1994): Atypical metabolism of deprenyl and its enantiomer, (s)-(+)-N,α-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem Res Toxicol 7:286-290.
21. Heinonen EH, Myllyla V, Sotaniemi K, Lammintausta R, Salonen JS, Anttila M, Savljarvim, Kotila M, Rinne UK (1989): Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 126:93-99.
22. Juorio AV, Li X-M, Paterson IA, Boulton AA (1994): Effects of MAO-B inhibitors on dopaminergic function: Role of 2-phenylethylamine and aromatic L-amino acid decarboxylase. In Lieberman et al. (eds): MAO Inhibition in Neurological Diseases. New York: Marcel Dekker, pp 181-200.
23. Kalász H, Kerecsen L, Knoll J, Pucsok J (1990): Chromatographic studies on the binding, action and metabolism of (-)-deprenyl. J Chromatog 499:589-599.
24. Karoum F, Chuang L-W, Eisler T, Calne DB, Liebowitz MR, Quitkin FM, Klein DF, Wyatt RJ (1982): Metabolism of (-)deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: A biochemical assessment. Neurology 32:503-509.
25. Kitani K, Kanai S, Sato Y, Ohta M, Ivo GO, Canillo M-C (1993): Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats - further evidence. Life Sci 52:281-288.
26. Knoll J, Dallo J, Yen TT (1990): Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. Life Sci 45:525-531.
27. Knoll J, Yen TT, Mikla I (1994): Sexually low performing male rats die earlier than their high performing peers and (-)deprenyl treatment eliminates this difference. Life Sci 15:1047-1057.
28. Knollema S, Aukema W, Hom H, Korf J, Ter-Horst GJ (1995): L-Deprenyl reduces brain damage in rats exposed to transient hypoxia-ischaemia. Stroke 26:1883-1887.
29. +-treated dopaminergic neurons. Eur J Pharmacol 269:R3-R4.
30. Li X-M, Juorio AV, Paterson IA, Zhu MY, Boulton AA (1992): Specific irreversible MAO-B inhibitors stimulate gene expression of aromatic l-amino acid decarboxylase in PC12 cells. J Neurochem 59:2324-2327.
31. Li X-M, Qi J, Juorio AV, Boulton AA (1993): Reduction in GFAP mRNA abundance induced by (-)deprenyl and other MAO-B inhibitors in C6 glioma cells. J Neurochem 61:1573-1576.
32. Li X-M, Juorio AV, Boulton AA (1995a): Some new mechanisms underlying the actions of (-)deprenyl: Possible relevance to neurodegeneration. Prog Brain Res 106:99-112.
33. Li X-M, Qi J, Juorio AV, Boulton AA (1995b): (-)Deprenyl enhances NGF-induced increase in superoxide dismutase mRNA in PC12 cells. J. Neurochem. 65(Suppl):S103D.
34. Li X-M, Konradi C, Qi J, Juorio AV, Boulton AA (1996): (-)Deprenyl down-regulates the low affinity NGF receptor (LNGFR, p75) in PC 12 cells. J Neurochem 66(Suppl):S11A.
35. Lieberman A, Olanow CW, Youdim MBH, Tipton K (1994): Monoamine Oxidase Inhibitors in Neurological Diseases. New York: Marcel Dekker.
36. Mangoni A, Grassi MP, Frattola L, Piolti R, Bani S, Mota A, Marconi A, Smirne S (1991): Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease. Eur J 31:100-107.
37. Mascher HJ, Kikuta C, Millendorfer A, Schiel H, Ludwig G (1997): Pharmacokinetcs and bioequivalence of the main metabolites of selegiline: Desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. Int J Clin Pharmacol Ther 35:9-13.
38. Milgram NW, Racine RJ, Nellis P, Mendonca A, Ivy GO (1990): Maintenance on L-deprenyl prolongs life in aged male rats. Life Sci 47:415-420.
39. Mytilineou C, Radcliffe PM, Leonardi EK, Werner P, Olanow WC (1997a): L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem 68:33-39.
40. Mytilineou C, Radcliffe PM, Olanow WC (1997b): L-(-)-Desmethylselegiline, a metabolite of selegiline(L-(-)-deprenyl) protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem 68:434-136.
41. Parkinson Study Group (1989): Effect of deprenyl on the progression of disability in early Parkinson's disease. N Eng J Med 321:1364-1371.
42. Parkinson Study Group (1993): Effect of tocopherol and deprenyl on the progression of disability in early Parkinsons disease. N Eng J Med 328:176-183.
43. Parnham MJ (1993): The history of L-deprenyl. In Szelenyi I (ed): Inhibitors of Monoamine Oxidase B: Pharmacology and Clinical Use in Neurodegenerative Disorders. Berlin: Birkhauser Verlag, pp 237-251.
44. Paterson IA, Tatton WG (1998): Antiapoptotic actions of monoamine oxidase B inhibitors. Adv Pharmacol 42:312-315.
45. Paterson IA, Juorio AV, Boulton AA (1990): 2-Phenylethylamine: A modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem 55:1827-1837.
46. Paterson IA, Davis BA, Durden DA, Juorio AV, Yu PH, Ivy G, Milgram W, Mendonca A, Wu P, Boulton AA (1995): Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca fascicularis) brain. Neurochem Res 20:1503-1510.
47. Paterson IA, Barber AJ, Gelowitz DL, Voll CL (1997a): (-)-Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neurosci Biobehav Rev 21:181-186.
48. Paterson IA, Davis BA, Durden DA, Boulton AA (1997b): Aliphatic propargylamines prevent hippocampal neuronal death induced by hypoxia-ischaemia. J Neurochem 69(Suppl):S137A.
49. Paterson, IA, Dyck LE, Durden DA, Davis BA, Lui Y, Boulton AA (1997c): The anti-apoptotic effects of 2HMP is due to a desmethyl metabolite. J Neurosci 23(Suppl 2):2254(abstract 880.6).
50. Paterson IA, Zhang D, Warrington RC, Boulton AA (1998): R-deprenyl and R-2-heptyl-n-methylproparglyamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. J Neurochem 70:515-523.
51. Philips SR (1981): Amphetamine, p-hydroxyamphetamine, and b-phenylethylamine in mouse brain and urine after (-)-and (+)-deprenyl administration. J Pharm Pharmacol 33:739-741.
52. Reynolds GR, Riederer P, Sandler M, Jellinger K, Seemann D (1978): Amphetamine and 2-phenylethylamine in post-mortem Parkinson brain after (-)deprenyl administration. J Neural Trans 43:271-277.
53. Ricci A, Mancini M, Strocchi P, Bongrani S, Bronzetti E (1992): Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridinium (AF64A) in the rat hippocampus: Sensitivity to treatment with the MAO-B inhibitor L-deprenyl. Drugs Exp Clin Res 18:163-171.
54. Roy E, Bedard PJ (1993): Deprenyl increases survial of rat foetal nigral neurones in culture. NeuroReport 4:1183-1186.
55. Ruehl WW, Bruyette DS, DePaoli A, Cotman CW, Head E, Milgram NW, Cummings BJ (1995): Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease - clinical presentation, cognitive testing, pathology and response to L-deprenyl therapy. Prog Brain Res 106:217-225.
56. Ruehl WW, Entriken TL, Muggenburg BA, Bruyette DS, Griffith WG, Hahn FF (1997): Treatment with L-deprenyl prolongs life in elderly dogs. Life Sci 61:1037-1044.
57. Ruehl WW, Neilson J, Hart B, Head E, Bruyette DS, Cummings BJ (1998): Therapeutic actions of L-deprenyl in dogs: A model of human brain aging. Adv Pharmacol 42:316-319.
58. Salo PT, Tatton WG (1992): Deprenyl reduces the death of motoneurones caused by axotomy. J Neurosci Res 31:394-400.
59. Sano M, Ernesto C, Thomas RG, Kauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LF (1997): A controlled trial of selegiline, alpha-tocopheral or both, as a treatment for Alzheimer's. N Engl J Med 336:1216-1222.
60. Schneider LS, Olin JT, Pawluczyk S (1997): Possible benefits of a combination of selegiline and cholinesterase inhibitors. In Judd LL, Saleta B, Filip V (eds): Basic and Clinical Science of Mental and Addictive Disorders. Basel: Karger, pp 235-237.
61. Seniuk NA, Henderson JT, Tatton WG, Roder JC (1994): Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by L(-)deprenyl. J Neurosci Res 37:278-286.
62. 0 boundary. Abstr Annu Meet Soc Cell Biologists.
63. Szelenyi I (1993): Inhibitors of MAO-B: Pharmacology and Clinical Use in Neurodegenerative Conditions. Berlin: Birhauser Verlag, pp 1-360.
64. Tariot PN, Cohen PM, Sunderland T, Newhouse PA, Yount D, Mellow AM, Weingartner H, Mueller EA, Murphy DL (1987): L-deprenyl in Alzheimer's disease: Preliminary evidence for behavioural change with MAO-B inhibitors. Arch Gen Psychiatry 44:427-433.
65. Tatton W, Chalmers-Redman RME (1996): Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration. Neurology 47(suppl 3):S171-S183.
66. Tatton WG, Greenwood CE (1991): Rescue of dying neurons: A new action for deprenyl in MPTP Parkinsonism. J Neurosci Res 30:666-672.
67. Tatton WG, Ju WYL, Holland DP, Tai C, Kwan M (1994): (-)Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572-1575.
68. Tatton WG, Chalmers-Redman RME, Ju WYH, Wadia J, Tatton NA (1997): Aopotosis in neurodegenerative disorders: Potential for therapy by modifying gene transcription. J Neural Trans 49:245-268.
69. Tetrud JW, Langston JW (1989): The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245:519-522.
70. Thomson CB (1995): Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462.
71. Yoshida T, Yamada Y, Yamamoto T, Kuroiwa Y (1986): Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: Relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 16:129-136.
72. Youdim MBH, Riederer P (1997): Understanding Parkinson's disease. Sci Am 276:52-59.
73. Yu PH (1989): Deamination of aliphatic amines of different chain lengths by rat liver MAO-A & B. J Pharm Pharmacol 41:205-208.
74. Yu PH, Davis BA, Boulton AA (1992a): Aliphatic propargylamines: potent, selective, irreversible MAO-B inhibitors. J Med Chem 35:3705-3713.
75. Yu PH, Davis BA, Boulton AA (1992b): Aliphatic Propargylamines as Specific MAO-B Inhibitors. USA patent #5,169,868.
76. Yu PH, Davis BA, Boulton AA (1993a): Aliphatic Propargylamines as MAO-B Inhibitors and Neuroprotective agents. PCT #92/00090 Europe, USA, Canada, Japan, Australia, and several other countries.
77. Yu PH, Davis BA, Boulton AA (1993b): Effect of structural modification of alkyl N-propargylamines on the selective inhibition of MAO-B activity. Biochem Pharmacol 46:753-757.
78. Yu PH, Davis BA, Durden DA, Barber A, Terleckyj I, Nicklas WG, Boulton AA (1994a): Neurochemical and neuroprotective effects of some aliphatic propargylamines: New selective nonamphetamine-like MAO-B inhibitors. J Neurochem 62:697-704.
79. Yu PH, Davis BA, Fang J, Boulton AA (1994b): Neuroprotective effect of some monoamine oxidase-B inhibitors against DSP-4 induced noradrenaline depletion in the mouse hippocampus. J Neurochem 63:1820-1828.
80. Yu PH, Davis BA, Zhang X, Zuo D-M, Fang J, Lai C-T, Li X-M, Paterson IA, Boulton AA (1995): Neurochemical, neuroprotective and neurorescue effects of aliphatic N-methylpropargylamines: New MAO-B inhibitors without amphetamine-like properties. Prog Brain Res 106:113-121.
81. Yu PH, Zhang X, Zuo DM, Lai CT, Tieu BA, Davis BA, Boulton AA (1998): Aliphatic N-methylpropargylamines as potential neurorescue agents. Restorative Neurol Neurosci (in press).
82. Zhang X, Zuo D-M, Yu PH (1995a): Neuroprotection of R(-)-deprenyl and N-2-hexyl-N-methylpropargylamine on DSP-4 induced degeneration of noradrenergic neurons in the rat locus coeruleus. Neuroscience 186:45-48.
83. Zhang X, Yu PH (1995b): Depletion of NOS activity in the rat dentate gyrus neurons by DSP-4 and protection by deprenyl. Brain Res Bull 38:307-311
84. Zhang X, Boulton AA, Yu PH (1996a): Expression of heat shock protein-70 and limbic seizure-induced neuronal death in the rat brain. Eur J Neurosci 8:1432-1440.
85. Zhang X, Boulton AA, Zuo DM, Yu PH (1996b): MK-801 induces apoptotic neuronal death in the rat retrosplenial cortex; Prevention by cycloheximide and R(-)-2-hexyl-N-methylpropargylaminc. J Neurosci Res 46:82-89.
86. Zhang X, Zuo DM, Davis BA, Boulton AA, Yu PH (1996c): Immunohistochemical evidence of neuroprotection by R(-)-deprenyl and N-(2-hexyl)-N-methylpropargylamine on DSP-4-induced degeneration of rat brain noradrenergic axons and terminals. J Neurosci Res 43:482-489.
87. Zhang X, Gelowitz DL, Lai CT, Boulton AA, Yu PH (1997): Gradation of kainic acid-elicited rat limbic seizures and expression of hippocampal heat shock protein-70. Eur J Neurosci 9:760-769.
88. Zuo DM, Yu PH (1995): Increased survival of dopaminergic neuroblastoma in co-cultures with C6 glioma by R(-)deprenyl. Prog Brain Res 106:199-205.